Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Pharmos (PARS) -- Ignore unavailable to you. Want to Upgrade?

To: DinoRia who wrote (420)	1/13/1999 7:40:00 PM
From: crysball	Read Replies (2) \| Respond to of 1386

Tamoxifen...........PARS 'back of the bus' pipeline product The prophlyactic characteristics of of Tamoxifen as it relates to Breast Cancer were mentioned on this evenings the NBC Nightly News. They also mentioned the adverse side effects........However, has anyone done a dose ranging study when Tamoxifen is used solely to prevent (as opposed to treat already diagnosed patients) Breast Cancer????? What's interesting about PARS Tamoxifen analogue is the recent discovery of what appears to be a strong link between an insecticide and Breast Cancer. If a statisically signifcant cause / effect correlation can be demonstrated [a second study is underway] then the fact that the population at risk has already been exposed (although the insecticide has been removed from the market it's still readily detectable in the food chain) and is essentially a ticking time bomb stored in body cells, or in the food chain....then the potential of using Tamoxifen prophylactically can be realized (if of course the safety profile can be demonstrated for a prophylactic dose). Now if that seems like like a lot of if/then's , it is, ...... but in the absence of any well articulated information from PARS management about a time/objective plan on the overall product pipeline all we 'poor' long suffering PARS stockholders can do is speculate.